Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Jun 01, 2020
Change of Director's Interest Notice
May 29, 2020
Final Director's Interest Notice
May 28, 2020
Virtual AGM online guide
May 28, 2020
Notice of Annual General Meeting/Proxy Form
May 27, 2020
Neuren announces changes to leadership team
May 07, 2020
Neuren commences first clinical trial for NNZ-2591
Apr 29, 2020
Appendix 4G
Apr 29, 2020
Annual Report 2019
Apr 17, 2020
Appendix 4C - quarterly
Apr 17, 2020
Q1 2020 Activity Report
Previous
1
2
3
4
5
6
Next
